A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer: EORTC-GU Group Protocol 30867

There is, a need to identify drugs with cytotoxic activity in bladder cancer which are tolerable even in patients with impaired renal function. Adriamycin (ADM) is recognized as such an active drug, and 4-epi-adriamycin (epi-ADM) has been developed as its less toxic analogue. Therefore the EORTC GU...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer & clinical oncology 1989-02, Vol.25 (2), p.389-390
Hauptverfasser:	FOSSA, S. D, SPLINTER, T, ROOZENDAAL, K. J, VEENHOF, K. H. N, PAVONE-MACALUSO, M, CALCIATI, A, DE PAUW, M, SYLVESTER, R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Biological and medical sciences Carcinoma, Transitional Cell - drug therapy Chemotherapy Drug Evaluation Epirubicin - adverse effects Epirubicin - therapeutic use Female Humans Leukopenia - chemically induced Male Medical sciences Middle Aged Nausea - chemically induced Pharmacology. Drug treatments Thrombocytopenia - chemically induced Urinary Bladder Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	There is, a need to identify drugs with cytotoxic activity in bladder cancer which are tolerable even in patients with impaired renal function. Adriamycin (ADM) is recognized as such an active drug, and 4-epi-adriamycin (epi-ADM) has been developed as its less toxic analogue. Therefore the EORTC GU Group performed a phase II study of epi-ADM in advanced urothelial cancer (EORTC Protocol 30867). Forty patients were entered in this study by 11 institutions.
ISSN:	0277-5379
DOI:	10.1016/0277-5379(89)90035-7